Enlivex Therapeutics Ltd. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Enlivex Therapeutics Ltd. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2015 to Q2 2024.
  • Enlivex Therapeutics Ltd. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$3.1M, a 54.4% increase year-over-year.
  • Enlivex Therapeutics Ltd. annual Net Income (Loss) Attributable to Parent for 2023 was -$29.1M, a 6.41% increase from 2022.
  • Enlivex Therapeutics Ltd. annual Net Income (Loss) Attributable to Parent for 2022 was -$31.1M, a 115% decline from 2021.
  • Enlivex Therapeutics Ltd. annual Net Income (Loss) Attributable to Parent for 2021 was -$14.5M, a 22.4% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$3.1M +$3.7M +54.4% Apr 1, 2024 Jun 30, 2024 6-K 2024-08-30
Q1 2024 -$4.14M +$3.08M +42.6% Jan 1, 2024 Mar 31, 2024 6-K 2024-08-30
Q2 2023 -$6.79M +$3.12M +31.5% Apr 1, 2023 Jun 30, 2023 6-K 2024-08-30
Q1 2023 -$7.22M +$1.01M +12.2% Jan 1, 2023 Mar 31, 2023 6-K 2024-08-30
Q2 2022 -$9.91M -$6.81M -219% Apr 1, 2022 Jun 30, 2022 6-K 2023-09-01
Q1 2022 -$8.23M Jan 1, 2022 Mar 31, 2022 6-K 2023-09-01
Q2 2021 -$3.11M -$67K -2.2% Apr 1, 2021 Jun 30, 2021 6-K 2022-08-22
Q2 2020 -$3.04M -$1.58M -108% Apr 1, 2020 Jun 30, 2020 6-K 2021-08-06
Q2 2019 -$1.46M Apr 1, 2019 Jun 30, 2019 6-K/A 2020-10-13
Q4 2016 -$16M -$3.07M +$1.76M +36.4% Oct 1, 2016 Dec 31, 2016 20-F 2017-02-24
Q3 2016 -$17.8M -$4.67M -$1.12M -31.5% Jul 1, 2016 Sep 30, 2016 20-F 2017-02-24
Q2 2016 -$16.7M -$3.69M +$1K +0.03% Apr 1, 2016 Jun 30, 2016 20-F 2017-02-24
Q1 2016 -$16.7M -$4.59M -$1.3M -39.3% Jan 1, 2016 Mar 31, 2016 20-F 2017-02-24
Q4 2015 -$15.4M -$4.83M Oct 1, 2015 Dec 31, 2015 20-F 2017-02-24
Q3 2015 -$3.55M Jul 1, 2015 Sep 30, 2015 20-F 2017-02-24
Q2 2015 -$3.69M Apr 1, 2015 Jun 30, 2015 20-F 2017-02-24
Q1 2015 -$3.3M Jan 1, 2015 Mar 31, 2015 20-F 2017-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.